secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001829126-24-007864
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharmaceuticals receives Nasdaq delisting notice for late Q3 filing; auditor Withum resigns
--------------------------------------------------------------------------------

- Received Nasdaq 5250 Notice on Nov 22 for failure to file Q3 10-Q; compliance plan due Jan 21, 2025, exception to May 19, 2025.
- Received Nasdaq 5605 Notice on Nov 25 for audit committee non-compliance due to Brynner Chiam's acting PEO/PFO role; cure until next annual meeting or Nov 6, 2025.
- Auditor WithumSmith+Brown resigned effective Nov 22, 2024, citing former CEO's resignation; no disagreements or reportable events.
- Company working to file Q3 10-Q and plans to appoint an additional independent director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912624007864/0001829126-24-007864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912624007864/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-007864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer